GSK - Ticker AI Digest

GSK plc 📰 2
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
GSK plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
GSK Data 2026-04-29 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (GSK) 2
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
1st Quarter Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK PLC reported strong Q1 2026 results, with total sales of £7.6 billion, a 2% increase in AER and 5% in CER. Specialty Medicines sales grew by 14% to £3.2 billion, driven by HIV, Respiratory, Immunology & Inflammation, and Oncology. Vaccines sales increased by 4% to £2.1 billion, led by Shingrix. General Medicines sales declined by 6% to £2.3 billion. Total operating profit rose by 9% to £2.293 billion, and Total EPS increased by 15% to 43.2p. Core operating profit grew by 10% to £2.650 billion, and Core EPS increased by 9% to 46.5p. GSK reaffirmed its 2026 guidance, expecting turnover growth of 3-5%, Core operating profit growth of 7-9%, and Core EPS growth of 7-9%. The company also highlighted pipeline progress, including new product approvals and regulatory filings, and continued its commitment to shareholder returns with a Q1 2026 dividend of 17p and a £1.7 billion share buyback program.
Here is the comparison of GSK's financials and debt year on year presented as an HTML table:
MetricQ1 2026Q1 2025Change
Total Sales (£m)7,6297,516+2% AER / +5% CER
Total Operating Profit (£m)2,2932,216+3% AER / +9% CER
Total EPS (pence)43.239.7+9% AER / +15% CER
Core Operating Profit (£m)2,6502,533+5% AER / +10% CER
Core EPS (pence)46.544.9+4% AER / +9% CER
Cash Generated from Operations (£m)1,3501,301+4%
Free Cash Flow (£m)815697+17%
Total Net Debt (£m)15,61313,947+12%
**Key Observations:** * **Sales Growth:** GSK reported a 2% increase in total sales on an AER basis and a 5% increase on a CER basis, driven by strong performance in Specialty Medicines. * **Profitability Improvement:** Both Total Operating Profit and Core Operating Profit increased year-on-year, with Core Operating Profit growing at a faster rate (10% CER) than Total Operating Profit (9% CER). * **EPS Growth:** Total EPS and Core EPS both increased, with Total EPS growing at a higher rate (15% CER) than Core EPS (9% CER). * **Cash Flow Improvement:** Cash generated from operations and free cash flow both increased, with free cash flow growing by 17%. * **Debt Increase:** Total net debt increased by 12%, primarily due to the acquisition of RAPT Therapeutics and share buybacks. **Note:** AER (Actual Exchange Rate) and CER (Constant Exchange Rate) are used to adjust for currency fluctuations.
AI 0
No items for this category on selected date.
Acquisitions 1
GSK 06:13
GSK plc
GSK completes acquisition of 35Pharma Inc.
Agreement 0
No items for this category on selected date.
Approvals 3
GSK 06:01
GSK plc
Blenrep approved in China for 2L+ multiple myeloma
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSKs Blenrep (belantamab mafodotin) has been approved in China for treating relapsed/refractory multiple myeloma in patients who have received at least one prior therapy. The approval is based on the DREAMM-7 trial, which showed a 42% reduction in death risk and nearly tripled median progression-free survival compared to a daratumumab-based triplet. Blenrep is the only anti-BCMA therapy approved in this setting in China, offering a new mechanism of action and fully outpatient administration, minimizing patient and healthcare burden. The approval follows priority review and Breakthrough Therapy Designation, addressing the growing incidence and mortality of multiple myeloma in China.
Approvals
GSK 06:01
GSK plc
Exdensur approved for CRSwNP in China
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSKs Exdensur (depemokimab) has been approved in China for treating chronic rhinosinusitis with nasal polyps (CRSwNP), offering a twice-yearly dosing regimen as the first ultra-long-acting biologic for this condition. The approval is based on positive results from the ANCHOR-1 and ANCHOR-2 trials, demonstrating significant improvements in nasal polyp size and obstruction. Exdensur addresses a critical unmet need, as many CRSwNP patients face uncontrolled symptoms despite existing treatments. This approval builds on its prior authorization for severe asthma in China and other regions, expanding access to this innovative therapy for respiratory diseases driven by type 2 inflammation.
Approvals
GSK 06:01
GSK plc
Exdensur approved for severe asthma in China
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Chinas NMPA approves GSKs Exdensur (depemokimab) for severe asthma treatment in adults and adolescents aged 12+, based on SWIFT trials showing reduced exacerbation rates. Exdensur is the first ultra-long-acting biologic in China for eosinophilic phenotype asthma, requiring only two doses annually. With over 2 million severe asthma patients in China, Exdensur aims to reduce hospitalization risks and improve disease management. GSK is also exploring Exdensur for other type 2 inflammation-related conditions, including chronic rhinosinusitis with nasal polyps and COPD.
Approvals
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 10
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 1
GSK 11:01
GSK plc
Efimosfermin granted US/EU regulatory designations
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Grants
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
GSK 06:01
GSK plc
1st Quarter Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK PLC reported strong Q1 2026 results, with total sales of £7.6 billion, a 2% increase in AER and 5% in CER. Specialty Medicines sales grew by 14% to £3.2 billion, driven by HIV, Respiratory, Immunology & Inflammation, and Oncology. Vaccines sales increased by 4% to £2.1 billion, led by Shingrix. General Medicines sales declined by 6% to £2.3 billion. Total operating profit rose by 9% to £2.293 billion, and Total EPS increased by 15% to 43.2p. Core operating profit grew by 10% to £2.650 billion, and Core EPS increased by 9% to 46.5p. GSK reaffirmed its 2026 guidance, expecting turnover growth of 3-5%, Core operating profit growth of 7-9%, and Core EPS growth of 7-9%. The company also highlighted pipeline progress, including new product approvals and regulatory filings, and continued its commitment to shareholder returns with a Q1 2026 dividend of 17p and a £1.7 billion share buyback program.
Here is the comparison of GSK's financials and debt year on year presented as an HTML table:
MetricQ1 2026Q1 2025Change
Total Sales (£m)7,6297,516+2% AER / +5% CER
Total Operating Profit (£m)2,2932,216+3% AER / +9% CER
Total EPS (pence)43.239.7+9% AER / +15% CER
Core Operating Profit (£m)2,6502,533+5% AER / +10% CER
Core EPS (pence)46.544.9+4% AER / +9% CER
Cash Generated from Operations (£m)1,3501,301+4%
Free Cash Flow (£m)815697+17%
Total Net Debt (£m)15,61313,947+12%
**Key Observations:** * **Sales Growth:** GSK reported a 2% increase in total sales on an AER basis and a 5% increase on a CER basis, driven by strong performance in Specialty Medicines. * **Profitability Improvement:** Both Total Operating Profit and Core Operating Profit increased year-on-year, with Core Operating Profit growing at a faster rate (10% CER) than Total Operating Profit (9% CER). * **EPS Growth:** Total EPS and Core EPS both increased, with Total EPS growing at a higher rate (15% CER) than Core EPS (9% CER). * **Cash Flow Improvement:** Cash generated from operations and free cash flow both increased, with free cash flow growing by 17%. * **Debt Increase:** Total net debt increased by 12%, primarily due to the acquisition of RAPT Therapeutics and share buybacks. **Note:** AER (Actual Exchange Rate) and CER (Constant Exchange Rate) are used to adjust for currency fluctuations.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
GSK 06:01
GSK plc
TESARO update on AnaptysBio Inc. litigation
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 39
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
1st Quarter Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK PLC reported strong Q1 2026 results, with total sales of £7.6 billion, a 2% increase in AER and 5% in CER. Specialty Medicines sales grew by 14% to £3.2 billion, driven by HIV, Respiratory, Immunology & Inflammation, and Oncology. Vaccines sales increased by 4% to £2.1 billion, led by Shingrix. General Medicines sales declined by 6% to £2.3 billion. Total operating profit rose by 9% to £2.293 billion, and Total EPS increased by 15% to 43.2p. Core operating profit grew by 10% to £2.650 billion, and Core EPS increased by 9% to 46.5p. GSK reaffirmed its 2026 guidance, expecting turnover growth of 3-5%, Core operating profit growth of 7-9%, and Core EPS growth of 7-9%. The company also highlighted pipeline progress, including new product approvals and regulatory filings, and continued its commitment to shareholder returns with a Q1 2026 dividend of 17p and a £1.7 billion share buyback program.
Here is the comparison of GSK's financials and debt year on year presented as an HTML table:
MetricQ1 2026Q1 2025Change
Total Sales (£m)7,6297,516+2% AER / +5% CER
Total Operating Profit (£m)2,2932,216+3% AER / +9% CER
Total EPS (pence)43.239.7+9% AER / +15% CER
Core Operating Profit (£m)2,6502,533+5% AER / +10% CER
Core EPS (pence)46.544.9+4% AER / +9% CER
Cash Generated from Operations (£m)1,3501,301+4%
Free Cash Flow (£m)815697+17%
Total Net Debt (£m)15,61313,947+12%
**Key Observations:** * **Sales Growth:** GSK reported a 2% increase in total sales on an AER basis and a 5% increase on a CER basis, driven by strong performance in Specialty Medicines. * **Profitability Improvement:** Both Total Operating Profit and Core Operating Profit increased year-on-year, with Core Operating Profit growing at a faster rate (10% CER) than Total Operating Profit (9% CER). * **EPS Growth:** Total EPS and Core EPS both increased, with Total EPS growing at a higher rate (15% CER) than Core EPS (9% CER). * **Cash Flow Improvement:** Cash generated from operations and free cash flow both increased, with free cash flow growing by 17%. * **Debt Increase:** Total net debt increased by 12%, primarily due to the acquisition of RAPT Therapeutics and share buybacks. **Note:** AER (Actual Exchange Rate) and CER (Constant Exchange Rate) are used to adjust for currency fluctuations.
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Bepirovirsen priority review US filing acceptance
GSK 11:01
GSK plc
Efimosfermin granted US/EU regulatory designations
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Grants
GSK 06:01
GSK plc
TESARO update on AnaptysBio Inc. litigation
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Blenrep approved in China for 2L+ multiple myeloma
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSKs Blenrep (belantamab mafodotin) has been approved in China for treating relapsed/refractory multiple myeloma in patients who have received at least one prior therapy. The approval is based on the DREAMM-7 trial, which showed a 42% reduction in death risk and nearly tripled median progression-free survival compared to a daratumumab-based triplet. Blenrep is the only anti-BCMA therapy approved in this setting in China, offering a new mechanism of action and fully outpatient administration, minimizing patient and healthcare burden. The approval follows priority review and Breakthrough Therapy Designation, addressing the growing incidence and mortality of multiple myeloma in China.
Approvals
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:13
GSK plc
GSK completes acquisition of 35Pharma Inc.
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
GSK presents positive data for BEHOLD 1 B7 H4 ADC
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Exdensur approved for CRSwNP in China
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSKs Exdensur (depemokimab) has been approved in China for treating chronic rhinosinusitis with nasal polyps (CRSwNP), offering a twice-yearly dosing regimen as the first ultra-long-acting biologic for this condition. The approval is based on positive results from the ANCHOR-1 and ANCHOR-2 trials, demonstrating significant improvements in nasal polyp size and obstruction. Exdensur addresses a critical unmet need, as many CRSwNP patients face uncontrolled symptoms despite existing treatments. This approval builds on its prior authorization for severe asthma in China and other regions, expanding access to this innovative therapy for respiratory diseases driven by type 2 inflammation.
Approvals
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:01
GSK plc
Total Voting Rights
GSK 06:01
GSK plc
ViiV completes changes to minority shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:06
GSK plc
Bepirovirsen accepted for review in China
GSK 06:01
GSK plc
Exdensur approved for severe asthma in China
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Chinas NMPA approves GSKs Exdensur (depemokimab) for severe asthma treatment in adults and adolescents aged 12+, based on SWIFT trials showing reduced exacerbation rates. Exdensur is the first ultra-long-acting biologic in China for eosinophilic phenotype asthma, requiring only two doses annually. With over 2 million severe asthma patients in China, Exdensur aims to reduce hospitalization risks and improve disease management. GSK is also exploring Exdensur for other type 2 inflammation-related conditions, including chronic rhinosinusitis with nasal polyps and COPD.
Approvals
GSK 06:01
GSK plc
Transaction in Own Shares

Today's AI

Today's AI Starts With News

2 live catalysts is opening Today’s AI for GSK.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-04-29 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
2 Today
Front Of Desk
GSK plc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
14:31 Today's Catalyst Director/PDMR Shareholding
Single-Ticker Today's AI
GSK signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for GSK plc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full GSK Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for GSK on 2026-04-29.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
73.9B
Enterprise Value
70.0B
Public Float
97.0
Broker Target
2082.7998
Shares Out
4.0B
Long Interest
96
Short Interest
4
Exchange
LSE
Currency Code
GBX
ISIN
GB00BN7SWP63
Market
LSE - MAIN MARKET
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

2 live alerts now opens the financials desk for GSK.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-04-29 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
2 Alerts
Front Of Desk
GSK plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
14:31 Today's Alert Director/PDMR Shareholding
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
0.68
Ex Divi
2026-05-14
Earnings Date
2026-04-28
Net Debt
14.6B
Cash
3.1B
EPS
1.42
Net Income
5.7B
Revenue
32.7B
Enterprise Value
70.0B
Trailing PE
12.9754
Forward PE
10.7875
Price Sales TTM
2.2549
Price Book MRQ
4.2281
EV Revenue
2.7789
EV EBITDA
9.0343
Financial Forecastist

Mixed financial engine

Revenue is accelerating +1.5% against the prior comparable period. Net margin is expanding by 1.2 pts. Net debt is coming down +449.8%.

Revenue +1.5% Net Income +7.0% FCF +0.1% Current Ratio 0.79x Forward Rev 8.9B
Mixed
Quarter Revenue
7.6B
+1.5%
vs prior comparable quarter
Net Margin
+22.8%
+1.2 pts
profitability pulse
Free Cash Flow
698.0M
+0.1%
cash conversion
Net Debt / EBITDA
5.6x
-449.8%
lower is cleaner
Revenue Engine

Latest quarter printed 7.6B with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 1.7B and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 3.4B while net debt is 15.6B. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
8.3B
Revenue Path
0.47
EPS / Earnings
Growth cue -0.1%
Q1 2026
Consensus
7.6B
Revenue Path
0.44
EPS / Earnings
Growth cue -0.0%
Q2 2026
Consensus
8.2B
Revenue Path
0.48
EPS / Earnings
Growth cue +0.0%
Q3 2026
Consensus
8.9B
Revenue Path
0.56
EPS / Earnings
Growth cue +0.0%
FY 2026
Consensus
33.8B
Revenue Path
1.78
EPS / Earnings
Growth cue +0.0%
FY 2027
Consensus
35.4B
Revenue Path
1.95
EPS / Earnings
Growth cue +0.1%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 7.6B 1.7B 698.0M 15.6B
Q4 2025 8.6B 636.0M 1.5B 14.6B
Q3 2025 8.5B 2.0B 1.3B -3.3B
Q2 2025 8.0B 1.4B 1.5B -3.6B
Q1 2025 7.5B 1.6B 697.0M -4.5B
Q4 2024 8.1B 414.0M 1.2B 13.3B

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 32.7B 5.7B 11.9B 6.0B
FY 2024 31.4B 2.6B 6.7B 3.6B
FY 2023 30.3B 4.9B 9.1B 4.4B
FY 2022 29.3B 15.0B 8.6B 5.1B
FY 2021 24.7B 4.4B 6.5B 5.0B

Structure DNA

Market Structure DNA

Yield Compounder profile with trend runway open

Price is 87.9% through the 52-week range, +1.5% vs 50DMA and +21.1% vs 200DMA. 48.4% of the register is locked by institutions and insiders, leaving 51.6% free float. Capital rhythm reads quarterly with forward yield near 3.4% and payout around 38.3%.

Trend runway open Institutional gravity Reliable income rhythm As Of 2026-04-19
Yield Compounder
Structure Score
77.1 / 100
Yield Compounder
Trend Stack
+1.5% / +21.1%
vs 50DMA / 200DMA
52W Position
87.9%
auction position inside the yearly range
Ownership Lock
48.4%
46.7% institutions | 1.7% insiders
Pressure Pocket
51.6% free float
Vendor short-float fields were not supplied
Capital Rhythm
Quarterly
Yield 3.4% | payout 38.3%
Trend Runway

Implied spot is 2,144.18 with the stock +1.5% vs 50DMA and +21.1% vs 200DMA. The tape is sitting 87.9% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 46.7% and insiders about 1.7%, locking roughly 48.4% of the register and leaving 51.6% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads quarterly with 4 event(s) in the last full year, a five-year average of 4.0, and stability score 100.0/100. Forward yield sits near 3.4% while payout is around 38.3%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

Quarterly
Year Dividend Count Context
2026 1 Current partial year
2025 4 Full year
2024 4 Full year
2023 4 Full year
2022 4 Full year
2021 4 Full year
2020 4 Full year
2019 4 Full year

Structure Facts

Live Snapshot
Implied Spot
2,144.18
derived from market cap / shares
52W High
2,265.00
upper auction edge
52W Low
1,267.16
lower auction edge
Beta
0.35
volatility character
Shares Out
4.0B
fully diluted count
Shares Float
3.9B
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
2026-02-19
-59 day(s) to ex-date
Dividend Pay
-
payment date not supplied
Last Split
4:5
2022-07-19

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.93
Institutions As Of
2026-05-01
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
11
Sale Director Dealing
18
Purchase TR1
1
Sale TR1
0
Broker Coverage Rows
44
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for GSK, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-04-29 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
2 Today
Catalyst Pulse
GSK plc has fresh news flow live now, so the tape is framing the chart workspace below.
14:31 Today's Catalyst Director/PDMR Shareholding
AI Charts Studio
GSK Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-04-29 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 10.79%
RSI Gauge
Price Change
AI Forecast